Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21683517rdf:typepubmed:Citationlld:pubmed
pubmed-article:21683517lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:21683517lifeskim:mentionsumls-concept:C2936626lld:lifeskim
pubmed-article:21683517lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:21683517lifeskim:mentionsumls-concept:C0048893lld:lifeskim
pubmed-article:21683517pubmed:issue1lld:pubmed
pubmed-article:21683517pubmed:dateCreated2011-7-4lld:pubmed
pubmed-article:21683517pubmed:abstractTextMacrophages play an important role in tumor inflammatory microenvironment, lipoxin (LX), the 'stop signal' for inflammation, has been extensively studied preclinically for its anti-inflammatory or inflammatory pro-resolving effect. Here, we showed that LXA(4) could promote the apoptosis and inhibit the proliferation, migration and angiogenesis of HepG2 hepatocarcinoma cells stimulated by lipopolysaccharide (LPS) or activated macrophage-conditioned media (ACM). Moreover, BML-111, the analog of LXA(4), effectively inhibited the proliferation, invasion and angiogenesis of tumor in H22 hepatocarcinoma cell bearing mice. These results showed that LXA(4) could be a possible candidate for liver cancer therapy, and blocking the activation of macrophages would be an effective drug target.lld:pubmed
pubmed-article:21683517pubmed:languageenglld:pubmed
pubmed-article:21683517pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21683517pubmed:citationSubsetIMlld:pubmed
pubmed-article:21683517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21683517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21683517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21683517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21683517pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21683517pubmed:statusMEDLINElld:pubmed
pubmed-article:21683517pubmed:monthOctlld:pubmed
pubmed-article:21683517pubmed:issn1872-7980lld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:MunN VNVlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:DaiM JMJlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:OTTBBlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:ChenYingYlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:WuPingPlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:LiuMiaoMlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:LiYongshengYlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:TangKeKlld:pubmed
pubmed-article:21683517pubmed:authorpubmed-author:YeDuyunDlld:pubmed
pubmed-article:21683517pubmed:copyrightInfoCopyright © 2011 Elsevier Ireland Ltd. All rights reserved.lld:pubmed
pubmed-article:21683517pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21683517pubmed:day1lld:pubmed
pubmed-article:21683517pubmed:volume309lld:pubmed
pubmed-article:21683517pubmed:ownerNLMlld:pubmed
pubmed-article:21683517pubmed:authorsCompleteYlld:pubmed
pubmed-article:21683517pubmed:pagination85-94lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:meshHeadingpubmed-meshheading:21683517...lld:pubmed
pubmed-article:21683517pubmed:year2011lld:pubmed
pubmed-article:21683517pubmed:articleTitleLipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment.lld:pubmed
pubmed-article:21683517pubmed:affiliationDepartment of Pathophysiology, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.lld:pubmed
pubmed-article:21683517pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21683517pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed